Gyre Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Gyre Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
1.7×Over the last 3 years its own operating cash covered its investment spending (capex) 1.7 times.
Higher than 72% of Healthcare companies in United States.
Cash Locked Ratio
$36For every $100 of sales, $36 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $18 tied up three years earlier.
More money tied up than 75% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
$19Sales grew 14% in 3 years; of every extra $100 of sales, $19 became extra profit.
Higher than 50% of Healthcare companies in United States.
Asset Productivity Ratio
+14% / +96%In 3 years sales changed by +14% while total assets changed by +96%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
1.6×Debt due within a year is covered 1.6 times by its yearly operating cash.
Higher than 73% of Healthcare companies in United States.
Cash Cushion Ratio
+8%Cash, after subtracting all debt, equals 8% of its market value (net cash).
Lower than 52% of Healthcare companies in United States.
Tangible Assets Ratio
96%Of every $100 the company owns, $96 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 77% of Healthcare companies in United States.
Tangible Net Worth Ratio
94%Of every $100 of net worth, $94 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 79% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Gyre Therapeutics, Inc. made a loss over the last year. Gyre Therapeutics, Inc. owes $0.28 for every $1 it owns. Net profit fell 58% in the year to Dec 2025, and grew 30% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGyre Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.76The share price is 5.76 times Gyre Therapeutics, Inc.'s book value per share, higher than 76% of Healthcare companies in United States.
Market cap
$621 MThe total market value of all of Gyre Therapeutics, Inc.'s shares at today's price (share price × number of shares), larger than 58% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$108 MWhat Gyre Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.02Net worth divided by the number of shares. The share price of $5.86 is 5.8 times this, which is the P/B above.
Return on equity (ROE)
-17.4%Gyre Therapeutics, Inc. lost 17.4% of its shareholders' money over the last year, higher than 67% of Healthcare companies in United States.
Owes vs Owns
0.28×Gyre Therapeutics, Inc. owes $0.28 for every $1 it owns (low), lower than 62% of Healthcare companies in United States.
Dividend yield
NoneGyre Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+10%Revenue rose 10% in the year to Dec 2025, and grew 4% a year on average over 3 years.
Profit growth
-58%Net profit fell 58% in the year to Dec 2025, and grew 30% a year on average over 3 years.
Profit margin
4.3%Gyre Therapeutics, Inc. keeps $4 of every $100 of revenue as net profit.
Cash quality
0.2×Cash from Gyre Therapeutics, Inc.'s business was 0.2× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Cash vs debt
Net cashGyre Therapeutics, Inc. held $51 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Gyre Therapeutics, Inc.: $621 M ÷ $108 M (30 Jun 2026) = 5.8.
What is Gyre Therapeutics, Inc.'s return on equity?
Gyre Therapeutics, Inc. lost 17.4% of its shareholders' money over the last year, higher than 67% of Healthcare companies in United States.
How much does Gyre Therapeutics, Inc. owe compared with what it owns?
Gyre Therapeutics, Inc. owes $0.28 for every $1 it owns (low), lower than 62% of Healthcare companies in United States.
Does Gyre Therapeutics, Inc. pay a dividend?
No. Gyre Therapeutics, Inc. does not currently pay a dividend.
Is Gyre Therapeutics, Inc.'s revenue growing?
Revenue rose 10% in the year to Dec 2025, and grew 4% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.